Janus Henderson Group PLC Sells 2,698 Shares of Iradimed Corporation (NASDAQ:IRMD)

Janus Henderson Group PLC reduced its holdings in Iradimed Corporation (NASDAQ:IRMD) by 10.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 24,207 shares of the medical equipment provider’s stock after selling 2,698 shares during the quarter. Janus Henderson Group PLC’s holdings in Iradimed were worth $1,217,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. 1620 Investment Advisors Inc. acquired a new stake in shares of Iradimed during the 2nd quarter worth approximately $25,000. Isthmus Partners LLC boosted its stake in Iradimed by 1.1% during the second quarter. Isthmus Partners LLC now owns 72,664 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 759 shares in the last quarter. Comerica Bank grew its holdings in Iradimed by 2,151.6% in the first quarter. Comerica Bank now owns 1,441 shares of the medical equipment provider’s stock worth $63,000 after purchasing an additional 1,377 shares during the period. Huntington National Bank increased its stake in Iradimed by 51.3% in the third quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock valued at $75,000 after purchasing an additional 504 shares in the last quarter. Finally, Gladius Capital Management LP raised its holdings in shares of Iradimed by 126.6% during the third quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider’s stock valued at $87,000 after purchasing an additional 965 shares during the period. 92.34% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO John Glenn sold 2,500 shares of Iradimed stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the sale, the chief financial officer now owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. This trade represents a 36.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 37.10% of the company’s stock.

Iradimed Price Performance

Shares of IRMD opened at $52.63 on Friday. Iradimed Corporation has a one year low of $40.18 and a one year high of $57.95. The company has a market cap of $666.82 million, a PE ratio of 36.05 and a beta of 0.82. The stock has a 50-day moving average of $52.58 and a 200-day moving average of $47.93.

Iradimed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 25th. Shareholders of record on Friday, November 15th were paid a $0.15 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.60 dividend on an annualized basis and a yield of 1.14%. Iradimed’s dividend payout ratio (DPR) is presently 41.10%.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.